SCM
BBIO icon

Sterling Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Sterling Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99.4K Buy
1,335
+306
+30% +$21.4K ﹤0.01% 1397
2026
Q1 		$76.4K Sell
1,029
-12
-1% -$870 ﹤0.01% 1485
2025
Q4 		$79.6K Buy
1,041
+662
+175% +$43.5K ﹤0.01% 1624
2025
Q3 		$19.7K Buy
379
+1
+0.3% +$49 ﹤0.01% 2156
2025
Q2 		$16.3K Sell
378
-628
-62% -$22.8K ﹤0.01% 1866
2025
Q1 		$34.8K Sell
1,006
-781
-44% -$26.3K ﹤0.01% 1516
2024
Q4 		$49K Buy
1,787
+1,514
+555% +$39.1K ﹤0.01% 1616
2024
Q3 		$6.95K Buy
+273
New +$7.17K ﹤0.01% 1651

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Sterling Capital Management's BBIO Position: Q2 2026 in Review

Sterling Capital Management increased its BridgeBio Pharma (BBIO) stake by 30% in Q2 2026, buying an estimated $21.4K and bringing the position to 1,335 shares worth $99.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1397.

Sterling Capital Management first reported a position in BBIO in Q3 2024 and has held it in 8 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Sterling Capital Management held 1,335 shares of BridgeBio Pharma worth $99.4K as of Q2 2026.
  • Sterling Capital Management bought 306 BridgeBio Pharma shares in Q2 2026, an estimated $21.4K.
  • BridgeBio Pharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1397 holding.
  • Sterling Capital Management first reported a position in BridgeBio Pharma in Q3 2024 and has held it in 8 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.